Internship

Spring 2025 Co-op Recombinant Mammalian MSAT

Ast

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Framingham, MA, USA

Must be able to relocate to Framingham, MA and work 40 hours/week, Monday-Friday.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
PowerPoint/Keynote/Slides
Requirements
  • Currently pursuing a Bachelor's or Master's degree in Biology, Biological/Biomedical Engineering, Biotechnology, Biochemistry, Chemistry or related field at an accredited college or university with the expectation that you will complete your current degree by the Spring of 2027
  • Must be enrolled in school the semester following your co-op with Sanofi.
  • Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op
  • Must have permanent US work authorization
  • Basic understanding of general concepts of biochemistry and laboratory procedures
  • Ability to work in Biosafety Level 1 environments and follow lab safety procedures
  • Proficiency in Microsoft Office software (excel, PowerPoint, word).
  • Excellent communication skills, written and verbal; able to effectively communicate with supervisor and team members
  • Highly organized with a keen attention to details
Responsibilities
  • Work on an MSAT development project
  • Evaluate and establish automation on Hamilton
  • Establish semi-automation methods for U/HPLCs
  • Establish sample preparation on the Hamilton.
  • Establish sample normalization, and sample clean-up for already established methods.
  • Establish Robustness and Reproducibility
  • Investigate Sample Vial vs Plate capabilities.
  • Collaborate with the MSAT project team; attend regular team meetings and share study progress and results.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, which help it maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

Grant

Total Funding

$2B

Headquarters

Paris, France

Founded

N/A

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's strong financial performance, as evidenced by its raised 2024 outlook, indicates robust growth and stability.
  • The company's strategic investments in innovative biotech firms, such as Ventyx Biosciences, enhance its pipeline and potential for breakthrough therapies.
  • Sanofi's Dupixent receiving a positive recommendation for expanded use in children demonstrates its leadership in addressing unmet medical needs.

What critics are saying

  • The highly competitive pharmaceutical market requires Sanofi to continuously innovate to maintain its market position.
  • Regulatory challenges in different regions could delay product approvals and impact revenue streams.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts and strategic partnerships, such as with Orano Med for radioligand therapies, set it apart in the competitive pharmaceutical landscape.
  • The company's global reach and focus on patient-centric solutions allow it to effectively navigate diverse regulatory environments and deliver innovative treatments worldwide.
  • Sanofi's investment in sustainable initiatives, like SureChill's 'Cooling as a Service' model, highlights its commitment to addressing healthcare challenges in emerging markets.

Help us improve and share your feedback! Did you find this helpful?